Glenmark Generics Ltd, a US subsidiary of Glenmark Pharmaceuticals Ltd, has gained full marketing rights through an exclusive partnership to begin distributing Azathioprine 50 mg tablets in the US.

Azathioprine is the generic equivalent of Imuran® tablets and is indicated as an adjunct for the prevention of rejection in renal homotransplantations (kidney transplantation). It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. Total sales for the 12-month period ending June 2008 was approximately $ 36 million as stated by IMS Health.

This product launch signifies Glenmark's commitment to enhance and augment its current portfolio of internal filings through the addition of external partnerships. Glenmark is authorised to distribute 130 SKUs in the US market. The company currently has 40 ANDAs in various stages of the approval process with USFDA.

In another development, Glenmark Generics has received ANDA approval from the USFDA for Ranitidine 150 mg & 300 mg tablets and will soon commence marketing and distribution of these products in the US market.